Recombinant adenoviral vectors comprising a splicing sequence
US6399587B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 2, 1999 |
| Grant date | Jun 4, 2002 |
| Priority date | — |
| Expiry date | Dec 2, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2840/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns a recombinant adenoviral vector driving from an adenovirus genome at least by deleting all or part of the E1 region, the adenoviral vector comprising an expression cassette of a gene of interest placed under the control of elements necessary for its expression in a host cell or a host organism, the elements required for its expression including at least a splicing sequence. The invention is characterized in that the splicing sequence is derived from a eukaryotic nuclear gene selected among the ovalbumen genes, &bgr; or &bgr;-globine, collagen and factor VIII of mammals or a synthetic splicing sequence. The invention also concerns a host cell and an infectious viral particle comprising such a vector, a method for preparing such a particle and their therapeutic or prophylactic use. The invention further concerns a pharmaceutical composition containing the adenoviral vector, the host cell or the viral particle.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.